We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
- Authors
Armstrong, Paul W.; Granger, Christopher B.; Abrams, Peter X.; Hamm, Christian; Holmes Jr., David; O'Neil, William W.; Todaro, Thomas G.; Vahanian, Alec; Van de Werf, Frans; Al-Khalidi, Hussein; Ardissino, Diego; Aylward, Phil; Betriu, Amadeo; Hochman, Judith; Huber, Kurt; James, Stefan; Lee, Kerry; Mahaffey, Kenneth W.; Moliterno, David; Montalescot, Gilles
- Abstract
This article focuses on a placebo-controlled phase 3 study of the effectiveness of the drug, pexelizumab, as an adjunct to percutaneous transliminal coronary intervention (PCI) in the treatment of patients with acute ST-elevation myocardial infarction. Patients received either placebo or pexelizumab prior to PCI. The main outcome measures were all-cause mortality up to the 30th day, death up to the 90th day and either death, cardiogenic shock or congestive heart failure through days 30 and 90. This study determined that mortality was low in the subjects studied and the administration of pexelizumab did not affect mortality rate.
- Subjects
THERAPEUTIC use of monoclonal antibodies; MYOCARDIAL infarction-related mortality; RANDOMIZED controlled trials; CLINICAL medicine research; MEDICAL experimentation on humans; HEALTH outcome assessment; PLACEBOS; DRUG efficacy
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 297, Issue 1, p43
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.297.1.43